Skip to main content

Table 2 Basic characteristics of patients

From: Early upregulation of AR and steroidogenesis enzyme expression after 3 months of androgen-deprivation therapy

 

BPH

n = 12

Prostate Cancer

P-Valuec

Primary PCa

n = 16

ADT-PCa

n = 10

 

Duration ≤ 12 Months n = 4

Duration > 12 Months n = 6

Age

64.2 ± 8.6

63.4 ± 7.0

58.75 ± 3.4

72 ± 9.3

0.05

Sample retrieval method

 Biopsy

5 (71%)

5 (31%)

–

–

–

 TUR-P

2 (29%)

5 (31%)

4 (100%)

6 (100%)

 

 Radical Prostatectomy

–

6 (38%)

–

–

 

Gleason Score

    

0.76

  < 7

–

4 (25%)

–

1 (17%)

 

 8–10

–

12 (75%)

4 (100%)

5 (83%)

 

T Staginga

    

0.91

 1

–

6 (37%)

–

–

 

 2

–

4 (25%)

2 (50%)

3 (50%)

 

 3

–

3 (19%)

–

1 (17%)

 

 4

–

3 (19%)

2 (50%)

2 (33%)

 

Lymphatic Involvements

–

1 (7%)

NE

NE

–

PSAa

9.5 (1.4–36.7)

49.3 (4.6–600)

24.13 (10.1–303.2)

203.2 (10.2–689)

0.01*

Prostate volumea

51.6 (28–73.6)

43.6 (13.4–80.5)

30.5 (28.6–36.68)

39.7 (27.6–94.2)

0.39

ADT Type

    

0.76

 Orchyde

–

–

2 (50%)

4 (67%)

 

 LHRH agonist + antiandrogen

–

–

2 (50%)

2 (33%)

 

ADT Treatment Duration

–

–

5 (3–9)

30 (15–70)

–

  1. N.E not evaluated
  2. a PSA and prostate volume are presented in median (min-max)
  3. b Sample retrieval method, T staging, and Lymphatic involvements are presented as percentages
  4. c Statistical significance was measured by comparing Primary PCa, ADT-PCa ≤ 12 months and > 12 months using Pearson chi square for Gleason score, and ADT Type; ANOVA for age; Kurskall Wallis test for T-stage, PSA level, and Prostate Volume
  5. d ADT treatment duration is presented in months
  6. *P-value < 0.05 is significant
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us